Rocket Pharmaceuticals Files 8-K for Material Agreement

TL;DR

Rocket Pharma signed a big deal, filing 8-K on 9/17.

AI Summary

Rocket Pharmaceuticals, Inc. filed an 8-K on September 17, 2025, reporting an entry into a material definitive agreement on September 11, 2025. The filing also includes financial statements and exhibits. The company, formerly known as Inotek Pharmaceuticals Corp, is incorporated in Delaware and headquartered in New York.

Why It Matters

This filing indicates a significant new agreement for Rocket Pharmaceuticals, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood.

Key Players & Entities

• Rocket Pharmaceuticals, Inc. (company) — Registrant
• Inotek Pharmaceuticals Corp (company) — Former company name
• September 11, 2025 (date) — Date of earliest event reported
• September 17, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• New York (location) — Principal executive offices city
• 646-440-9100 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common stock, $0.01 par value RCKT The Nasdaq Global Ma
• $482,040 — titled to receive a lump sum payment of $482,040, consistent with the Company's Severanc
• $30,045 — eive a lump sum healthcare allowance of $30,045, equal to the cost of COBRA premiums fo
• $582,156 — Dr. Patel an aggregate retainer fee of $582,156 under the Consulting Agreement and Dr.

Filing Documents

• ef20055707_form8k.htm (8-K) — 32KB
• ef20055707_ex10-1.htm (EX-10.1) — 76KB
• ef20055707_ex10-2.htm (EX-10.2) — 51KB
• logo1.jpg (GRAPHIC) — 7KB
• 0001140361-25-035251.txt ( ) — 329KB
• rckt-20250911.xsd (EX-101.SCH) — 4KB
• rckt-20250911_lab.xml (EX-101.LAB) — 21KB
• rckt-20250911_pre.xml (EX-101.PRE) — 16KB
• ef20055707_form8k_htm.xml (XML) — 4KB

01

Item 1.01. Entry into a Material Definitive Agreement In connection with the previously announced departure of Dr. Kinnari Patel to accept a role as a venture partner at RTW Investments LP, on September 11, 2025, Rocket Pharmaceuticals, Inc. (the "Company") entered into a Separation and Release Agreement (the "Separation Agreement") with Dr. Patel. Pursuant to the Separation Agreement, Dr. Patel agreed to a general release of claims in favor of the Company and its affiliates and agreed to certain restrictive covenants. The Separation Agreement also provides for the following: Dr. Patel shall be entitled to receive her current salary and medical, dental and vision coverage benefits through December 31, 2025 (the "Separation Date") in accordance with regular payroll procedures and shall be paid for all accrued and unused paid time off as of the Separation Date; Dr. Patel shall be entitled to receive a lump sum payment of $482,040, consistent with the Company's Severance and Change in Control Program, provided that she deliver an executed release of claims (the "Release of Claims") within seven days of the Separation Date; The Company shall offer Dr. Patel a Consulting Agreement to serve as a consultant to the Company beginning on the expiration of the revocation period provided for in the Release of Claims; and Dr. Patel shall be receive a lump sum healthcare allowance of $30,045, equal to the cost of COBRA premiums for ten (10) months. On September 11, 2025, Dr. Patel and the Company entered into a Consulting Agreement to be effective beginning on the expiration of the revocation period provided for in the Release of Claims (the "Effective Date"). The Consulting Agreement shall begin on the Effective Date and continue through December 31, 2026 (the "Consulting Period"), unless earlier terminated by either party pursuant to the terms therein. The Company shall pay Dr. Patel an aggregate retainer fee of $582,156 under the Consulting Agreement and Dr. Patel sha

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Separation and Release Agreement, dated as of September 11, 2025, by and between Rocket Pharmaceuticals, Inc. and Kinnari Patel. 10.2 Consulting Agreement, dated as of September 11, 2025, by and between Rocket Pharmaceuticals, Inc. and Kinnari Patel. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rocket Pharmaceuticals, Inc. Date: September 17, 2025 By: /s/ Martin Wilson Martin Wilson General Counsel and Chief Corporate Officer, SVP

View Full Filing

View this 8-K filing on SEC EDGAR